Literature DB >> 9136233

Dyspnea: pathophysiology and assessment.

C Ripamonti1, E Bruera.   

Abstract

Dyspnea is frequently a multicausal and devastating symptom among advanced cancer patients. It occurs in 21%-78.6% of patients days or weeks before death and is often difficult to control. The genesis and pathophysiology of dyspnea as a symptom still has not been well understood. Dyspnea is frequently associated with abnormalities in the mechanisms that regulate normal breathing; however, the actual expression of dyspnea by a patient results from a complex interaction between the abnormalities in breathing and the perception of those abnormalities in the central nervous system. The production of dyspnea has to be related to the activation of mechanoreceptors both in the respiratory muscles and in the lung, even in the absence of increased muscle respiratory activity. Respiratory muscle weakness appears to be an important cause of dyspnea in malnourished, asthenic, and cachectic cancer patients. This might also explain why about 24% of dyspneic cancer patients do not present cardiac/pulmonary disease. In addition, two other possible mechanisms of dyspnea have been proposed: chemoreceptor stimulation and efferent activity from the respiratory center by direct ascending stimulation. These factors and the assessment tools used in patients with chronic dyspnea are summarized in this review.

Entities:  

Mesh:

Year:  1997        PMID: 9136233     DOI: 10.1016/s0885-3924(96)00327-2

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  14 in total

1.  Health care providers' use and knowledge of the Edmonton Symptom Assessment System (ESAS): is there a need to improve information and training?

Authors:  Daniela Carli Buttenschoen; Jarad Stephan; Sharon Watanabe; Cheryl Nekolaichuk
Journal:  Support Care Cancer       Date:  2013-09-13       Impact factor: 3.603

2.  Development and validation of a prognostic scale for hospitalized patients with terminally ill cancer in China.

Authors:  Yu Huang; Qingsong Xi; Shu Xia; Xushi Wang; Yong Liu; Chao Huang; Wei Zheng; Shiying Yu
Journal:  Support Care Cancer       Date:  2013-09-07       Impact factor: 3.603

3.  The relationship of cancer symptom clusters to depressive affect in the initial phase of palliative radiation.

Authors:  Richard Benoit Francoeur
Journal:  J Pain Symptom Manage       Date:  2005-02       Impact factor: 3.612

Review 4.  Pathophysiology and diagnosis of dyspnea in patients with advanced cancer.

Authors:  Gudrun Pohl; Jan Gaertner
Journal:  Wien Med Wochenschr       Date:  2009-12

5.  Patients' experience of oxygen therapy and dyspnea: a qualitative study in home palliative care.

Authors:  Darin Jaturapatporn; Erica Moran; Chris Obwanga; Amna Husain
Journal:  Support Care Cancer       Date:  2010-03-21       Impact factor: 3.603

Review 6.  Exercise therapy in the management of dyspnea in patients with cancer.

Authors:  Graeme J Koelwyn; Lee W Jones; Whitney Hornsby; Neil D Eves
Journal:  Curr Opin Support Palliat Care       Date:  2012-06       Impact factor: 2.302

7.  The relationship between dyspnea and patient satisfaction with quality of life in advanced cancer.

Authors:  Digant Gupta; Christopher G Lis; James F Grutsch
Journal:  Support Care Cancer       Date:  2006-11-21       Impact factor: 3.603

Review 8.  Symptoms of and Palliative Treatment for Unresectable Skin Cancer.

Authors:  Hiroyuki Goto; Yoshio Kiyohara; Masahisa Shindo; Osamu Yamamoto
Journal:  Curr Treat Options Oncol       Date:  2019-03-27

9.  Construction of a new, objective prognostic score for terminally ill cancer patients: a multicenter study.

Authors:  Sang-Yeon Suh; Youn Seon Choi; Jae Yong Shim; Young Sung Kim; Chang Hwan Yeom; Daeyoung Kim; Shin Ae Park; Sooa Kim; Ji Yeon Seo; Su Hyun Kim; Daegyeun Kim; Sung-Eun Choi; Hong-Yup Ahn
Journal:  Support Care Cancer       Date:  2009-04-21       Impact factor: 3.603

10.  A prospective study on C-reactive protein as a prognostic factor for survival time of terminally ill cancer patients.

Authors:  Sang-Yeon Suh; Hong-Yup Ahn
Journal:  Support Care Cancer       Date:  2007-01-18       Impact factor: 3.359

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.